CVA
GILD icon

Central Valley Advisors’s Gilead Sciences GILD Stock Holding History

Central Valley Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
1,769
+5
+0.3% +$659 0.06% 177
2026
Q1 		$246K Buy
+1,764
New +$247K 0.07% 165

Other funds holding GILD

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Central Valley Advisors's GILD Position: Q2 2026 in Review

Central Valley Advisors increased its Gilead Sciences (GILD) stake by 0.28% in Q2 2026, buying an estimated $659 and bringing the position to 1,769 shares worth $223K. The position accounts for 0.06% of the portfolio, ranked #177.

Central Valley Advisors first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $246K in Q1 2026. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Central Valley Advisors held 1,769 shares of Gilead Sciences worth $223K as of Q2 2026.
  • Central Valley Advisors bought 5 Gilead Sciences shares in Q2 2026, an estimated $659.
  • Gilead Sciences made up 0.06% of Central Valley Advisors's portfolio in Q2 2026, its #177 holding.
  • Central Valley Advisors first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Central Valley Advisors's Gilead Sciences position peaked at $246K in Q1 2026.
  • 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Central Valley Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.